MELBOURNE-BASED Cann Group has announced it will receive its first plant material and start cultivation of medicinal cannabis in the coming days after securing the necessary permits from the government's Office of Drug Control (ODC).
The company has been issued with one medicinal cannabis permit and two cannabis research permits.
These permits will facilitate the establishment of breeding plants for propagation purposes, a research program being undertaken with the CSIRO to develop unique cannabis extracts and the supply of plant material for manufacturing into medicinal cannabis products for patient use.
The first plants being cultivated by Cann are expected to be harvested by early Aug this year.
Harvested material from the plants cultivated under the medicinal cannabis permit are being supplied under a commercial agreement, the terms of which, including manufacturer details, volume, and price will be kept confidential, the company said.
The company added that it was working toward specific scale-up milestones throughout this year.
Cann ceo Peter Crock said, "We will start cultivation at our southern facility, while work continues on preparing our northern facility, also in Melbourne, which will have a larger cultivation and production capacity."
The above article was sent to subscribers in Pharmacy Daily's issue from 31 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 May 17